Longeveron (LGVN) Other financing activities (2021 - 2026)

Longeveron's (LGVN) quarterly Other financing activities came in at $1.3 million in Q1 2026, down 85.0% quarter-over-quarter from $8.5 million in Q2 2025.

Longeveron (LGVN) Other financing activities (2021 - 2026) Analysis & Trends

Longeveron's Other financing activities history runs 4 years deep, the most recent figure standing at $1.3 million for Q1 2026.

  • On a quarterly basis, Other financing activities changed N/A year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $9.8 million, a 146.94% increase from a year earlier, with the FY2024 full-year figure at $16.2 million, up 16421.43% from the prior year.
  • Other financing activities fell to $1.3 million in Q1 2026 per LGVN's latest filing, from $8.5 million in the prior quarter.
  • Across five years, Other financing activities topped out at $8.5 million in Q2 2025 and bottomed at $3000.0 in Q4 2024.
  • The 3-year median for Other financing activities is $3.6 million (2024), against an average of $3.9 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Longeveron 3.97 Mn -11.79 Mn 264,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 1.28 Mn
Mar 31, 2026 1.28 Mn
Jun 30, 2025 8.50 Mn
Jun 30, 2025 8.50 Mn
Dec 31, 2024 3,000.00
Dec 31, 2024 3,000.00
Sep 30, 2024 5.85 Mn
Sep 30, 2024 5.85 Mn
Dec 31, 2021 -26.69 Mn
Dec 31, 2021 -26.69 Mn
Jun 30, 2021 24.20 Mn
Jun 30, 2021 24.20 Mn